The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinomaHui Zeng, Jingjing Li, Qi Xu et al.|Frontiers in Immunology|2023Cited by 17
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Jieer Ying, Shurui Zhou et al.|Nature Communications|2025Cited by 12
Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II–IIIJingjing Li, Jieer Ying, Qi Xu et al.|Translational Cancer Research|2020Cited by 2
Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize DoseJingjing Li, Jieer Ying, Shurui Zhou et al.|Research Square|2024Cited by 1